Extraordinary General Meeting 2017

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, are hereby given notice to attend an extraordinary shareholders’ meeting to be held at the company’s premises on Västra Trädgårdsgatan 15 in Stockholm, Sweden, on Monday, 6 February 2017 at 9:00 a.m. (CET).

Upcoming events

Silent Period

-

FDA - Oncologic Drugs Advisory Committee (ODAC) Meeting

The US Food and Drug Administration, FDA, has announced a forthcoming public advisory committee meeting of the Oncologic Drugs Advisory Committee (ODAC), on October 28, 2021 concerning Oncopeptides’ product Pepaxto. The information is in line with the FDA safety alert on July 28, where the FDA stated that a public meeting may be hold to discuss the safety findings from the OCEAN study.

Interim Report Q3 2021

08:00 CET

63rd ASH Annual Meeting & Exposition

-

American Society of Hematology (ASH) 63rd annual meeting with both in-person and virtual participation at the Georgia World Congress Center in Atlanta, Georgia. ASH Annual Meeting & Exposition is the largest event in malignant and non-malignant hematology.

Silent Period

-

Year-end report 2021

08:00 CET

Silent Period

-

Silent Period

-